Dong-E-E-Jiao stock: Analyst Forecast
000423.SZFor Dong-E-E-Jiao, analysts expect revenue of $1.08B (up 7.9%) and adjusted earnings per share of $0.44 (up 9.7%) on average for fiscal year 2026. For 2027 they expect revenue of $1.17B (up 9%) and adjusted earnings per share of $0.49 (up 9.9%). That is the average of the estimates of 8 analysts.
Daily figure as of 20 Nov 2026
Reported and Expected
| Fiscal year | Type | Revenue | Growth | Net income | Net margin | EPS | Analysts |
|---|---|---|---|---|---|---|---|
| 2023 | Reported | $707.29M | 16.7% | $172.63M | 24.4% | $0.27 | |
| 2024 | Reported | $888.12M | 25.6% | $233.55M | 26.3% | $0.36 | |
| 2025 | Reported | $996.55M | 12.2% | $260.81M | 26.2% | $0.41 | |
| 2026 | Estimate | $1.08B | 7.9% | $285.64M | 26.6% | $0.44 | 8 |
| 2027 | Estimate | $1.17B | 9.0% | $313.84M | 26.8% | $0.49 | 8 |
Earnings per share in the estimates are usually adjusted, the way analysts calculate them. The reported figure is the statutory one and can therefore differ.
What the Estimates Show
In 5 of 7 quarters, Dong-E-E-Jiao missed the analysts' expectation for revenue and beat it once. For earnings per share, Dong-E-E-Jiao beat the analysts' expectation in 0 of 8 quarters and missed it in 4. The expected revenue growth for 2026 of +7.9% is below the average of fiscal years 2020 to 2025 of +14.3% per year.
In the report of 23 Oct 2026, earnings per share came in 2.7% below the expectation. Since 19 Nov 2026, analysts have barely changed their earnings estimate for 2026. Revenue estimates stayed almost unchanged over the same period. The expected net margin stays at about 26.8% in 2026 and 2027.
A reported figure within 2% of the expectation counts as in line.
How Dong-E-E-Jiao Compares
For the next fiscal year, analysts expect revenue growth of +9% for Dong-E-E-Jiao, less than for 53% of the 66 other stocks in the Drug Manufacturers (Specialty & Generic) industry with estimates. The highest expected revenue growth in the Drug Manufacturers (Specialty & Generic) industry belongs to Eton Pharmaceuticals, PharmaEssentia and Harrow Health.
Estimates of Industry Peers
Among industry peers, analysts expect the strongest revenue growth at Rovi (+14.3%) and the weakest at China Resources Sanjiu Medical & Pharmaceutical (+6.3%).
| Stock | Expected revenue growth | Forward P/E |
|---|---|---|
| China Resources Sanjiu Medical & Pharmaceutical | +6.3% | no data |
| Gland Pharma | +14.2% | 35.3 |
| Ipca Laboratories | +11.8% | 27.9 |
| Rovi | +14.3% | 20 |
| Siegfried Holding | +9% | 14.9 |
Revenue growth here means the next fiscal year against the current one, both analyst averages.
Forecast and Fair Value
MEQIRI's fair value for Dong-E-E-Jiao is $8.45, 5.9% above the share price. Its cash flow part uses the analysts' estimates for the first year.
Why There Is No Price Target Here
MEQIRI deliberately does not show price targets or buy and sell recommendations, because they are opinions about the future share price. Revenue and earnings, by contrast, can be checked against every report.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026; valuation signal Fairly valued since 18 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
